Dr. John Cush RheumNow
5 years 6 months ago
#RNL2021 coverage from @uptoTate
"Dr. Robert Wang: 91% of uveitis is non-infectious and located in the front of the eye - "anterior uveitis/iritis." 50% of anterior uveitis patients are +HLA B27! "
#RheumNowLive
Dr. John Cush RheumNow
5 years 6 months ago
News Feature: Upadacitinib Clinical Efficacy in Psoriatic Arthritis
https://t.co/gdAnqEFk3n https://t.co/PNYwhRFTEK
Dr. John Cush RheumNow
5 years 6 months ago
Thanks @doctorRBC for sharing this from #RNL2021
"Dr. N Haroon talking about SpA treatment
-TNFi can reduce spinal radiographic progression
-Better to taper biologics in AxSpA than stopping
-JAKinibs are coming "
Dr. John Cush RheumNow
5 years 6 months ago
News Feature: HLA B27 Iritis - RNL 2021 Highlights by Dr. Rachel Tate ( @uptoTate ) #RNL2021 #RheumNow
https://t.co/SlftHnhD6z https://t.co/utjOU0rfBP
Dr. John Cush RheumNow
5 years 6 months ago
News Feature: Inflammatory Conditions Up the Risk of Premature Myocardial Infarction
https://t.co/gbPpAYJGFg https://t.co/ValdJWGyxl
Dr. John Cush RheumNow
5 years 6 months ago
News Feature: Aortic Calcification and Lumbar Fracture Risk in Older Men
https://t.co/6gcoP9EFey #RheumNow https://t.co/BTTrYAoyNp
Dr. John Cush RheumNow
5 years 6 months ago
In the UK, NICE has recommended Kineret (anakinra) for use as 1st line biologic Rx in systemic JIA and adult-onset still’s disease (AOSD); but pts must first fail a DMARD - the latter is unfortunate as systemic Sxs of Still's do not respond to usual DMARDs.https://t.co/BNdqhLy9jg
Dr Jack Cush reviews the news and Journal reports and takes "Back Talk" questions from viewers.
Dr. John Cush RheumNow
5 years 6 months ago
From @doctorRBC #RNL2021 coverage "Avoid the lawsuit... “warty” appearing skin lesions in a lupus can be confused as skin cancer on shave biopsy when in fact it could be VERRUCOUS LUPUS which can be treated with HCQ. Perform a deeper biopsy. - Dr. Clay Cockrell " #RheumNow
Dr. John Cush RheumNow
5 years 6 months ago
Comparison of oral and parenteral MTX shows oral MTX in RA is non inferior to subcutaneous MTX treatment (in 640 RA pts) with regard to disease activity, but oral MTX had fewer adverse events than SC ( 41% vs 52%, p= 0.005). https://t.co/828kcG53iz
Dr. John Cush RheumNow
5 years 6 months ago
Matched cohort Nurses’ Health Study looked at 283 pre‐RA pts (mean 9.7 years before RA Dx) and and 842 controls; 21% pre‐RA were ACPA+. ACPA+ was associated with increased risk of COPD (HR 3.04) that was not seen in ACPA- pts. https://t.co/HNB11eAiva
Dr. John Cush RheumNow
5 years 6 months ago
Dr. Olga Petryna ( @drpetryna) weighing the future Rx in RA by Dr. Fleischmann:
-CD22, new IL6i & GM-CSF show promises but far form being available
-bDMARD or tsDMARD after MTX but work better wMTX
-JAKS better choice for mono-therapy but safety is a concern
#RNL2021
Dr. John Cush RheumNow
5 years 6 months ago
#RNL2021 coverage from @doctorRBC
ACR’s conditional recommendations for tx of specific RA populations #RheumNow https://t.co/3uo9x42bPX
Dr. John Cush RheumNow
5 years 6 months ago
Retrospective study of 267 adults w/ Henoch-Schönlein purpura (AKA IgA vasculitis (IgAV) shows more arthritis, enteritis & renal Dz, higher comorbidity scores (2.6 vs1.5) & higher risk of Serious infx (OR 8.4) and death (MRR 2.06) than gen population https://t.co/ihK6JPbLFm

